AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05121298
Drug: upadacitinib 15mg/day
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
Trial: NCT05330390
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epilepsy, treatment with levetiracetam
Trial: NCT06496308
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
Trial: NCT06496308
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine IV will be administered as per the schedule specified in the respective arm.
Trial: NCT06496308
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab IV will be administered as per the schedule specified in the respective arm.
Trial: NCT06496308
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax PO will be administered as per the schedule specified in the respective arm.
Trial: NCT05933967
Drug: Orelabrutinib+R-CHOP
RxNorm normalized name: pantolactone, (R)-
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
Trial: NCT04492241
Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
RxNorm normalized name: Ginkgo biloba leaf extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
Trial: NCT04492241
Drug: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution
RxNorm normalized name: Ginkgo biloba leaf extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
Trial: NCT06138353
Drug: Shuxuening injection or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
Trial: NCT04803175
Drug: Sacubitril-Valsartan
RxNorm normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
Trial: NCT04803175
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
Trial: NCT05363722
Drug: sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab 200 mg IV d1 Q3W
Trial: NCT05363722
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 15 mg/kg IV d1，Q3W
Trial: NCT01037387
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Current treatment according to the ATS/ERS guidelines
Trial: NCT06219967
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal alone
Trial: NCT06219967
Drug: Activated Charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal mixed with cola
Trial: NCT00149981
Drug: everolimus (RAD)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus
Trial: NCT05153603
Drug: Olaparib mono-maintenance therapy
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
Trial: NCT05538949
Drug: EB-203
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8.
Trial: NCT05124028
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg po qd 6 weeks
Trial: NCT04870073
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
Trial: NCT06368414
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
Trial: NCT04991571
Drug: Zibotentan (Treatment A)
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan capsule will be administered orally as multiple doses in Part 1 and as single dose in Part 2.
Trial: NCT04991571
Drug: Dapagliflozin (Treatment A)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin tablet will be administered orally as single dose in Part 2.
Trial: NCT04991571
Drug: Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
Trial: NCT04991571
Drug: Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zibotentan/Dapagliflozin tablet will be administered orally as single dose in Part 2.
Trial: NCT06280768
Drug: SHR-2004 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
Trial: NCT05133687
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
Trial: NCT05215470
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Trial: NCT05215470
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Trial: NCT04019262
Drug: Temozolomide Oral Product
RxNorm normalized name: temozolomide Oral Product
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)
Trial: NCT05578287
Drug: Anti-HER2 ADC
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
Trial: NCT06429501
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT04742673
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
Trial: NCT05513014
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with Psoriasis who initiated Secukinumab
Trial: NCT05092828
Drug: Intrathecal Morphine Injection
RxNorm normalized name: morphine Injection
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
Trial: NCT05092828
Drug: Pain Relieving
RxNorm normalized name: Pain Relieving
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
Trial: NCT05609955
Drug: MgSO4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment group who received intravenous magnesium sulfate therapy with 20% magnesium sulfate regimen, 30mg/kg body weight dissolved in 100ml NaCl in 1 hour intravenously
Trial: NCT06145360
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the impact of incorporating Empagliflozin, an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor, into the existing therapeutic regimen of Insulin+Metformin+DPP4 inhibitor (DPP4I) in poorly controlled type 2 diabetes mellitus (T2DM
Trial: NCT06145360
Drug: Insulin+Metformin+DPP4 inhibitor (DPP4I)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Trial: NCT06496841
Drug: Transnasal Sphenopalatine ganglion block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
Trial: NCT06496841
Drug: Ultrasound-guided suprazygomatic sphenopalatine ganglion block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
Trial: NCT06102512
Drug: LOXO-783
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT06442566
Drug: Buprenorphine Patch
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
Trial: NCT04305769
Drug: Alanyl-glutamine
RxNorm normalized name: ALANYL-GLUTAMINE
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
Trial: NCT06196658
Drug: anti-EX02 CAR T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg
Trial: NCT06044233
Drug: STI-1558
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI-1558 test preparation and reference preparation
Trial: NCT04934696
Drug: BMS-986166
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04934696
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04672980
Drug: RTX-321
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX-321 monotherapy
Trial: NCT04964505
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT04964505
Drug: Uproleselan
RxNorm normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04964505
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00063869
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06328179
Drug: Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VHEA -Induction Phase Regimen/Consolidation therapy after remission
Trial: NCT06389344
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Trial: NCT06248515
Drug: Sacituzumab govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
Trial: NCT06271681
Drug: 23-valent pneumococcal polysaccharide vaccine
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
Trial: NCT05293600
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
Trial: NCT05293600
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
Trial: NCT05293600
Drug: Atomoxetine and eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
Trial: NCT05733741
Drug: Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.
Trial: NCT05363501
Drug: IM Naloxone Injection
RxNorm normalized name: naloxone Injection
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
Trial: NCT05363501
Drug: Naloxone Nasal Spray
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
Trial: NCT05363501
Drug: Naloxone Nasal Swab
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg naloxone nasal swab administered in nostril
Trial: NCT05363501
Drug: Naloxone Nasal Swab
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg naloxone nasal swab administered in nostril
Trial: NCT05363501
Drug: Naloxone Nasal Swab
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg naloxone nasal swab administered in nostril
Trial: NCT05363501
Drug: Naloxone Nasal Swab
RxNorm normalized name: naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg naloxone nasal swab administered in nostril
Trial: NCT05654701
Drug: Palopegteriparatide (TransCon PTH)
RxNorm normalized name: Palopegteriparatide
DrugBank: Palopegteriparatide (DB18676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug Palopegteriparatide (TransCon PTH) is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
Trial: NCT04229355
Drug: DEB-TACE plus Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-eluting bead transarterial chemoembolization plus sorafenib (400 mg/d, po, bid)
Trial: NCT04229355
Drug: DEB-TACE plus Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug-eluting bead transarterial chemoembolization plus lenvatinib (8 mg/d, po, qd)
Trial: NCT04229355
Drug: DEB-TACE plus PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-eluting bead transarterial chemoembolization plus PD-1 inhibitor